CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS is a solid oral pharmaceutical formulation containing Cefpodoxime and Ofloxacin as its active pharmaceutical ingredients. The combination is developed as a dual-active tablet in which both ingredients must be accurately incorporated into the same dosage form while maintaining consistency across individual tablets. From a formulation-development perspective, this type of product requires careful evaluation of active ingredient characteristics, excipient compatibility, powder flow, compression behavior, and finished-product stability.
The formulation may contain suitable pharmaceutical excipients such as diluents, binders, disintegrants, glidants, lubricants, and other processing aids. The selection and concentration of these excipients depend on the finalized formulation design and manufacturing technology.
For pharmaceutical companies developing a broad product portfolio, maintaining consistency in the composition and manufacturing process is particularly important. A professionally developed formulation should have clearly defined specifications covering raw materials, processing parameters, in-process controls, finished-product testing, and packaging requirements.
The presence of two active ingredients also makes blend uniformity an important consideration during formulation development. Proper material handling, controlled dispensing, and validated mixing procedures help support consistent distribution of both active components throughout the batch.
The formulation development of CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS involves studying the physical and chemical characteristics of both active pharmaceutical ingredients. Particle size, bulk density, flowability, moisture content, and compressibility can influence the behavior of the powder blend during manufacturing.
Cefpodoxime and Ofloxacin may have different physical characteristics, so formulation scientists generally evaluate their compatibility with each other and with the selected excipients. Preformulating studies can include assessment of physical appearance, moisture behavior, particle characteristics, and potential interactions between formulation components.
A suitable blending strategy is essential for achieving uniform distribution. Depending on the formulation, individual materials may be screened or milled before controlled blending. Premixing of selected components can also be considered where appropriate. The sequence of addition and mixing time should be established based on formulation-development studies.
Uniformity is particularly important in combination formulations because the finished tablet must contain the intended quantity of each active ingredient. Sampling plans and blend-uniformity assessments can therefore form an important part of process development.
Manufacturing begins with the receipt, identification, testing, and release of approved raw materials. Cefpodoxime, Ofloxacin, and the required excipients are dispensed according to the approved master manufacturing formula using calibrated weighing equipment.
The materials may undergo sieving to achieve appropriate particle characteristics before entering the blending stage. Depending on the powder properties and selected technology, the formulation may be processed using direct compression, dry granulation, or another suitable manufacturing approach.
During compression, the prepared blend is fed into the tablet compression machine under controlled operating conditions. Important parameters may include tablet weight, compression force, machine speed, thickness, hardness, and physical appearance. These parameters are monitored to maintain consistency throughout the manufacturing batch.
In-process testing can be conducted at defined intervals. Tablet weight variation, dimensions, hardness, friability, and appearance may be assessed during production. Monitoring these characteristics helps identify potential process variation at an early stage.
The compression process must balance adequate mechanical strength with appropriate disintegration and dissolution characteristics. Excessive compression or unsuitable formulation parameters may affect the physical and pharmaceutical performance of the finished tablet, making process optimization an important part of product development.
Quality control is a critical stage in the manufacture of CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS. Finished-product testing is performed according to the approved product specification and applicable regulatory requirements.
Analytical evaluation may include identification and assay of Cefpodoxime and Ofloxacin, related substances, dissolution, disintegration, uniformity of dosage units, average weight, friability, hardness, and other relevant quality attributes.
Since two active ingredients are present, analytical methods should be capable of accurately identifying and quantifying each component without interference from the other ingredients or excipients. Appropriate validated analytical procedures help provide reliable and reproducible test results.
Dissolution testing can be used to evaluate the release behavior of the active ingredients from the tablet formulation. Disintegration testing provides information about the physical breakdown of the tablet under specified laboratory conditions.
Quality assurance activities extend beyond laboratory testing. Documentation, batch manufacturing records, equipment qualification, process controls, deviation management, change control, and environmental monitoring may all contribute to an organized pharmaceutical quality system.
Packaging development is an essential component of the overall product strategy. CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS may be packed in suitable pharmaceutical blister packs or other approved container-closure systems depending on the stability requirements of the formulation.
Packaging materials are selected after considering protection from moisture, light, oxygen, mechanical stress, and other environmental factors that may influence product quality. Container-closure compatibility is also evaluated to ensure that the packaging system does not adversely affect the tablet during storage.
Stability studies are performed under defined conditions to evaluate changes in the product over time. Samples may be examined for appearance, assay, degradation products, dissolution, and other specified quality parameters at predetermined intervals.
The final packaging should provide adequate protection during storage, transportation, handling, and distribution. Clear labeling and batch identification are also important for product traceability and inventory management.
CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS can be incorporated into a diversified pharmaceutical product portfolio where combination formulations, dosage-form variety, quality systems, and professional packaging are important considerations. A well-organized portfolio generally requires consistency across formulation development, manufacturing, testing, documentation, and supply-chain operations.
For pharmaceutical companies, maintaining defined product specifications allows production teams and quality-control departments to work according to standardized procedures. Consistent packaging and product presentation can further strengthen the overall identity of a pharmaceutical range.
Combination tablets also require careful inventory planning because multiple active pharmaceutical ingredients and supporting excipients must be sourced and controlled according to their respective specifications. Proper vendor qualification and raw-material testing can contribute to dependable manufacturing operations.
For businesses expanding their PCD Pharma Franchise portfolio, CEFPODOXIME 200MG WITH OFLOXACIN 200MG TABLETS can be included alongside other tablet, capsule, syrup, dry-syrup, injection, and nutraceutical formulations. A structured approach to formulation quality, analytical testing, packaging, documentation, and manufacturing consistency helps create a professional pharmaceutical portfolio designed for organized distribution and long-term business growth.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech